Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 16, 2023, titled "Nidlegy Phase III PIVOTAL trial meets the study s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma".